Skip to main content

Table 6 PRO EQ-5D and QLQ-C30 subscale scores at baseline and safety follow-up

From: Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study

 

KRASPRO analysis set

PRO analysis set

WT KRAS(n = 76)a

MT KRAS(n = 54)a

Overall (n = 137)a

Baseline

Safety follow-up

Baseline

Safety follow-up

Baseline

Safety follow-up

Mean (SD) EQ-5D subscale scores b

  Mobility

1.13 (0.34)

1.17 (0.38)

1.13 (0.34)

1.12 (0.42)

1.12 (0.33)

1.16 (0.41)

  Self care

1.05 (0.23)

1.14 (0.35)

1.13 (0.44)

1.15 (0.51)

1.08 (0.32)

1.15 (0.43)

  Usual activities

1.29 (0.56)

1.39 (0.60)

1.35 (0.59)

1.34 (0.65)

1.30 (0.56)

1.38 (0.62)

  Pain/discomfort

1.45 (0.58)

1.53 (0.56)

1.53 (0.58)

1.46 (0.56)

1.46 (0.57)

1.51 (0.56)

  Anxiety/depression

1.26 (0.50)

1.25 (0.44)

1.39 (0.49)

1.33 (0.48)

1.31 (0.49)

1.30 (0.46)

Mean (SD) QLQ-C30 functioning scores c

  Physical

71.7 (20.1)

71.3 (20.5)d

71.9 (19.6)

78.6 (10.5)d

72.5 (19.8)

74.3 (18.2)d

  Role

26.1 (33.4)

30.0 (33.3)

32.1 (35.0)

28.8 (29.8)

27.4 (33.7)

30.3 (31.2)

  Cognitive

10.2 (17.7)

13.3 (19.7)

13.6 (22.7)

14.1 (18.2)

11.0 (19.6)

14.4 (19.6)

  Emotional

24.3 (23.1)

22.1 (20.0)

26.5 (22.9)

14.9 (19.0)

24.6 (22.6)

19.8 (20.5)

  Social

25.8 (33.4)

25.7 (27.8)

23.5 (32.6)

16.7 (21.2)

23.6 (32.5)

22.4 (24.9)

Mean (SD) QLQ-C30 symptom scores e

  Fatigue

29.0 (27.8)

31.9 (28.3)

35.4 (31.6)

31.3 (22.6)

31.4 (28.8)

32.3 (26.0)

  Pain

19.1 (27.4)

22.9 (27.4)

25.3 (29.6)

19.3 (26.1)

21.2 (27.9)

21.6 (26.6)

  Nausea/vomiting

3.3 (10.6)

7.6 (14.2)

8.6 (19.1)

10.6 (19.9)

5.3 (14.6)

8.6 (16.8)

Mean (SD) QLQ-C30 single-item scores e

  Dyspnoea

17.1 (27.5)

21.0 (28.1)

23.5 (30.8)

21.2 (21.8)

19.2 (28.5)

21.3 (26.4)

  Insomnia

29.8 (35.8)

23.8 (28.7)

28.4 (32.0)

23.2 (27.0)

29.4 (34.2)

25.0 (28.9)

  Appetite loss

18.9 (31.0)

15.2 (30.6)

25.9 (35.3)

15.2 (27.8)

20.7 (32.4)

14.4 (28.4)

  Constipation

13.3 (23.2)

4.8 (14.3)

14.2 (25.6)

12.1 (23.3)

14.0 (23.8)

9.7 (22.0)

  Diarrhoea

20.7 (30.6)

12.4 (23.0)

19.1 (30.8)

22.2 (27.2)

19.5 (30.0)

18.1 (25.6)

  Financial impact

8.1 (20.5)

7.6 (18.2)

6.8 (17.6)

11.5 (26.2)

7.2 (18.8)

9.4 (22.0)

  1. aActual ‘n’ number may differ according to subscale item and time point (data from fewer patients were available at safety follow-up vs. baseline); bHigher scores indicate a better level of functioning of a greater degree of symptomology depending on subscale; cA higher score indicates a better level of functioning/health; cA higher score indicates a better level of functioning/health; dData not available at safety follow-up, data reported at week 48 instead; eA higher score indicates a greater degree of symptomology.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us